{"id":"df535bec433f","type":"article","url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","title":"Aanvullende farmacologische strategieën voor restrisicoreductie na revascularisatie","title_en":"Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["atherosclerose","atorvastatine","bempedoïnezuur","biomarkers-cardiovasculair","bloeddrukbehandeling","cetp-remmers","clear-outcomes","diabetes-en-hart","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","farmaco-economie","gepersonaliseerde-geneeskunde","hdl-cholesterol","laminopathie","ldl-cholesterol","lipidenverlaging","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","ouderen","pcsk9-remmers","pelacarsen","perifeer-vaatlijden","plaquekarakterisatie","statines"],"journal":"EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology","doi":"10.4244/EIJ-D-25-00598","source_url":"https://doi.org/10.4244/EIJ-D-25-00598","authors":["Asahi Oshima","Patrick W Serruys","Scot Garg","J William McEvoy","David A Wood","Torsten Doenst","David P Taggart","John D Puskas","Ajmal Shajahan","Faisal Sharif","Kotaro Miyashita","Akihiro Tobe","Tsung-Ying Tsai","Pruthvi C Revaiah","Fidelma Dunne","Roxana Mehran","Matthew J Budoff","John J Kastelein","Eric S G Stroes","Ramzi Khamis","Wolfgang Koenig","Yoshinobu Onuma"],"significance":6,"published":"2026-02-16","source_date":"2026-02-16","image":"","kennis":["https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"This EuroIntervention review discussed adjunctive pharmacological strategies for reducing residual cardiovascular risk after coronary revascularization, covering anti-inflammatory, lipid-lowering, and antithrombotic approaches beyond standard therapy.","created":"2026-07-03T10:25:11Z","updated":"2026-07-03T13:24:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Farmacologische behandeling blijft essentieel bij atherosclerotisch vaatlijden. Naast LDL-cholesterolverlaging met statines worden nieuwe strategieën onderzocht om het restrisico na myocardrevascularisatie te verminderen, waaronder combinatietherapieën en ontstekingsremmende middelen.","abstract_original":"Pharmacological treatment remains vital in the effective management of atherosclerotic cardiovascular disease (ASCVD). Low-density lipoprotein (LDL) cholesterol-lowering therapies, such as statins, have consistently demonstrated robust efficacy in the primary and secondary prevention of cardiovascular events. The introduction of ezetimibe, bempedoic acid, and proprotein convertase subtilisin/kexin type 9 inhibitors have further strengthened the effectiveness of LDL cholesterol management, particularly in patients who are statin intolerant or who remain at high risk despite maximal tolerated statin therapy. In addition to managing LDL cholesterol, addressing residual lipid risk by targeting elevated triglyceride and lipoprotein(a) levels and low high-density lipoprotein cholesterol levels has emerged as a potentially important therapeutic consideration, as these are increasingly recognised as independent cardiovascular risk factors. Concurrently, inflammation is increasingly acknowledged as a significant contributor to atherogenesis and subsequent cardiovascular events. Clinical trials examining anti-inflammatory therapies, such as colchicine and interleukin-1β inhibitors (e.g., canakinumab), have demonstrated beneficial effects in reducing cardiovascular events independent of lipid modification. This narrative review provides an updated overview targeted specifically at physicians performing coronary artery bypass grafting or percutaneous coronary intervention. It summarises current evidence regarding established lipid-lowering therapies, emerging therapeutic approaches to address residual lipid risk, and the evolving role of anti-inflammatory interventions in the comprehensive management of ASCVD."}